A Phase Ib Study of NeoVax in Combination With CDX-301 and Nivolumab or Pembrolizumab and in Patients With Melanoma
Latest Information Update: 29 Mar 2024
At a glance
- Drugs CDX 301 (Primary) ; NEO-PV 01 (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Adverse reactions
- 25 Mar 2024 Planned number of patients changed from 20 to 30.
- 08 Mar 2023 Planned primary completion date changed from 31 Jan 2023 to 31 Jan 2025.
- 16 Mar 2022 Status changed from not yet recruiting to recruiting.